Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €16.59 EUR
Change Today -1.82 / -9.90%
Volume 150.0
26C On Other Exchanges
As of 1:55 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

nantkwest inc (26C) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/5/15 - €28.76
52 Week Low
09/1/15 - €14.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NANTKWEST INC (26C)

Related News

No related news articles were found.

nantkwest inc (26C) Related Businessweek News

No Related Businessweek News Found

nantkwest inc (26C) Details

NantKwest, Inc., a biotechnology company, develops immunotherapeutic agents for various clinical conditions. It is initiating a Phase II clinical trial for its activated natural killer product candidate for the treatment of virally-induced cancers, such as polyomavirus induced Merkel cell carcinoma, human Papillomavirus, induced cervical cancer, and head and neck cancer, as well as infectious diseases comprising Ebola and other viral, fungal, and bacterial infections. The company also holds right to commercialize a range of genetically modified derivatives that kills cancer and virally infected cells. In addition, it focuses on to initiate a Phase I/II clinical trials for target activated natural killer product candidate for acute myeloid leukemia and bulky hematological cancers. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in Cardiff-by-the-Sea, California.

11 Employees
Last Reported Date: 07/16/15
Founded in 2002

nantkwest inc (26C) Top Compensated Officers

President, Chief Operating Officer and Execut...
Total Annual Compensation: $908.6K
Vice President of Research and Development
Total Annual Compensation: $479.6K
Compensation as of Fiscal Year 2014.

nantkwest inc (26C) Key Developments

NantKwest, Inc.(NasdaqGS:NK) added to NASDAQ Composite Index

NantKwest, Inc. has been added to Nasdaq Composite Index.

Conkwest Seeks Acquisitions

Conkwest, Inc. plans to use portion of net proceeds from offering to in-license, acquire or invest in complementary business, technologies, products or assets.

Conkwest, Inc. Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-19-2015 05:00 PM

Conkwest, Inc. Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-19-2015 05:00 PM. Venue: Club Med, Sandpiper Bay, Florida, United States. Speakers: Barry J. Simon, Chief Executive Officer and President.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
26C:GR €16.59 EUR -1.82

26C Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 26C.
View Industry Companies

Industry Analysis


Industry Average

Valuation 26C Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2,446.8x
Price/Book 21.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3,103.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NANTKWEST INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at